All Resources
Access a curated library of reports, policy submissions, data insights, and other materials informing Canada’s life sciences ecosystem.
Filter by
Time to Listing: Canada’s public plans cover fewer new medicines and take longer than most OECD countries to approve them
Public plans in Canada cover fewer medicines than in other OECD20 countries and take longer to be approved. For rare-disease medicines, this gap is even larger.
